SCHEMBL23218403

SCHEMBL23218403

COC(=O)Cc1cccc(C(N)=O)c1OCc1coc2ccc(-c3cccc(CN)c3)cc12

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CFD P00746 7/20 0.45
F11 P03951 2/20 0.39
TPSB2 P20231 2/20 0.39
PLG P00747 1/20 0.39
PLAU P00749 1/20 0.39
KLKB1 P03952 1/20 0.39
F7 P08709 1/20 0.39
FFAR1 O14842 1/20 0.37
TP53 P04637 1/20 0.36
HTR1A P08908 1/20 0.34
HTR1D P28221 1/20 0.34
HTR2C P28335 1/20 0.34
TGFBR1 P36897 1/20 0.34
NQO2 P16083 1/20 0.34
MAOA P21397 1/20 0.34
MAOB P27338 1/20 0.34
MTNR1B P49286 2/20 0.33
SUCNR1 Q9BXA5 1/20 0.33
MTNR1A P48039 1/20 0.33
MAPT P10636 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29852668 1.00 CFD (0.45) CFDF11TPSB2PLGPLAU
SCHEMBL23218212 0.92 CFD (0.41) CFDF11TPSB2PLGPLAU
SCHEMBL29852602 0.92 CFD (0.41) CFDF11TPSB2PLGPLAU
SCHEMBL29592685 0.90 CFD (0.51) CFDF11TPSB2PLGPLAU
SCHEMBL23218976 0.90 CFD (0.51) CFDF11TPSB2PLGPLAU
SCHEMBL23229122 0.87 CFD (0.40) CFDF11TPSB2PLGPLAU
SCHEMBL29853127 0.86 CFD (0.44) CFDF11TPSB2PLGPLAU
SCHEMBL28736109 0.86 CFD (0.44) CFDF11TPSB2PLGPLAU
SCHEMBL23218448 0.85 CFD (0.41) CFDF11TPSB2PLGPLAU
SCHEMBL29852812 0.85 CFD (0.41) CFDF11TPSB2PLGPLAU

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12558341-B2 Oral complement factor D inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2026-02-24 US disclosed
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-06-12 US disclosed
CN-114502168-A Oral complement factor D inhibitors 拜奥克里斯特制药公司 2022-05-13 CN disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12558341-B2 Oral complement factor D inhibitors CFD, CFH, CFB CFD 1/4885F11 24/4885TPSB2 419/4885
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS CFD, CFH, CFB CFD 1/4885F11 14/4885TPSB2 498/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.